A government panel has found that hormone therapy is not recommended for menopausal women.

U.S. Preventive Services Task Force are definitively decisive in their findings that the risks of hormone replacement therapy outweigh the benefits to menopausal women over 50.

The new recommendations are based on a review of data, published Monday in the Annals of Internal Medicine, covering nine clinical trials over the last decade.
The standard of care shifted for many doctors after the Women’s Health Initiative trial was halted, but updated recommendations from the task force are important because many patients still have questions, and many doctors are reluctant to let go of old prescribing habits, Crandall said.

Hormone replacement therapy was given routinely to women to mitigate symptoms that might develop and to prevent the development of cardiovascular diseases.